Overview
ALPHA-1062IN: Potential first treatment for Cognitive Impairment with Mild Traumatic Brain Injury (mTBI)
- Plans to develop and commercialize ALPHA-1062IN in TBI and related disorders from Alpha Cognition, Inc.
- US Cognitive Impairment market is estimated at $17B+ with no currently approved product
- ALPHA-1062IN pre-clinical data has demonstrated positive cognitive effects and protects brain from damage
- No toxicity observed in completed studies
- Patents extending to 2043
Upcoming Inflection Points and Milestones
• Formulation and Stability work completion – Q3 2024
• DOD bomb blast study completion – Q4 2024
• Toxicity study completion – Q4 2024
• Anticipated IND acceptance – 1H 2025
• PH2 clinical study initiation – 1H 2025
• Potential path to Fast Track designation – 2H 2025